Humacyte Management

Management Kriterienprüfungen 2/4

Humacyte's CEO ist Laura Niklason , ernannt in Jan 2004, hat eine Amtszeit von 20.42 Jahren. Die jährliche Gesamtvergütung beträgt $2.63M , bestehend aus 23% Gehalt und 77% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von $1.70M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 2.8 Jahre.

Wichtige Informationen

Laura Niklason

Geschäftsführender

US$2.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	23.0%
Amtszeit als Geschäftsführer	20.4yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.8yrs

Jüngste Management Updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Laura Niklason im Vergleich zu den Einnahmen von Humacyte verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$3m	US$604k	-US$111m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$500k	-US$12m
Sep 30 2022	n/a	n/a	US$34m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	US$11m	US$500k	-US$26m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$69m
Dec 31 2020	US$619k	US$75k	-US$67m

Vergütung im Vergleich zum Markt: LauraDie Gesamtvergütung ($USD2.63M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.37M).

Entschädigung vs. Einkommen: LauraDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Laura Niklason (61 yo)

20.4yrs

Amtszeit

US$2,625,702

Vergütung

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Laura Niklason	Founder	20.4yrs	US$2.63m	0.20% $ 1.7m
Dale Sander	CFO, Chief Corporate Development Officer & Treasurer	3.6yrs	US$1.35m	0.019% $ 159.3k
Heather Prichard	Chief Operating Officer	5.1yrs	US$1.27m	0% $ 0
Juliana Blum	Co-Founder & Executive Advisor	no data	keine Daten	keine Daten
Sabrina Osborne	Executive Vice President of Business Strategy & People	no data	keine Daten	keine Daten
William Scheessele	Chief Commercial Officer	2.8yrs	keine Daten	0.013% $ 109.5k
Shamik Parikh	Chief Medical Officer	2.2yrs	US$1.53m	0% $ 0
Harold Alterson	Senior Vice President of Quality	1.8yrs	keine Daten	keine Daten
Yang Cao	Chief Regulatory Officer	1.8yrs	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: HUMADas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Laura Niklason	Founder	20.4yrs	US$2.63m	0.20% $ 1.7m
Gordon Binder	Independent Director	2.8yrs	US$71.76k	0.18% $ 1.5m
Max Wallace	Independent Director	19yrs	US$76.76k	0.054% $ 455.1k
Brady Dougan	Director	19.4yrs	US$71.76k	0.43% $ 3.6m
Susan Windham-Bannister	Independent Director	2.8yrs	US$71.76k	0% $ 0
Todd Pope	Independent Director	no data	US$76.76k	0% $ 0
Rajiv Shukla	Director	2.8yrs	US$71.76k	1.52% $ 12.8m
Kathleen Sebelius	Independent Chairman of the Board	8.8yrs	US$96.76k	0% $ 0
Michael Constantino	Independent Director	no data	US$79.26k	0.0078% $ 65.2k
Diane Seimetz	Independent Director	2yrs	US$71.76k	0% $ 0
Emery Brown	Independent Director	2.8yrs	US$71.76k	0% $ 0
C. Green	Independent Director	1.8yrs	US$71.76k	0% $ 0

2.8yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: HUMADie Vorstandsmitglieder gelten nicht als erfahren ( 2.8 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Humacyte Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Founder exercised options to buy US$280k worth of stock.

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 126%

Price target decreased to US$11.25

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.76 loss in 2Q 2021)

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Humacyte, Inc. to Report Q2, 2022 Results on Aug 12, 2022

High number of new directors

Humacyte, Inc. Announces Results Evaluating the Use of the Small-Diameter (3.5mm) Human Acellular Vessel for Coronary Artery Bypass Grafting in a Non-Human Primate Model

High number of new directors

Humacyte, Inc. Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel(TM) (HAV(TM)) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors

Humacyte, Inc. Presents New Immunogenicity Data on Human Acellular Vessels(Tm) (Havs(Tm))

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Humacyte, Inc. to Report Q1, 2022 Results on May 13, 2022

Price target decreased to US$14.67